Anoro Ellipta

— THERAPEUTIC CATEGORIES —
  • Asthma/COPD
PAGE CONTENTS
  • Jump to Section
  • Generic Name & Formulations
  • Indications
  • Dosage and Administration
  • Contraindications
  • Boxed Warnings
  • Warnings/Precautions
  • Pharmacokinetics
  • Interactions
  • Adverse Reactions
  • Clinical Trials
  • Note
  • Patient Counseling

    • Anoro Ellipta Generic Name & Formulations

    Legal Class

    Rx

    General Description

    Umeclidinium 62.5mcg, vilanterol 25mcg; per ­inhalation; dry pwd for oral inhalation.

    Pharmacological Class

    Anticholinergic + long-acting beta-2 agonist (LABA).

    How Supplied

    Dry pwd inhaler—30 doses

    Manufacturer

    GlaxoSmithKline

    Generic Availability

    NO

    Anoro Ellipta Indications

    Indications

    Maintenance treatment of COPD.

    Limitations of Use

    Not indicated for relief of acute bronchospasm or for treatment of asthma.

    Anoro Ellipta Dosage and Administration

    Adult

    1 inhalation once daily.

    Children

    Not established.

    Anoro Ellipta Contraindications

    Contraindications

    Severe allergy to milk proteins. Use of LABA without inhaled corticosteroid (ICS) in those with asthma.

    Anoro Ellipta Boxed Warnings

    Not Applicable

    Anoro Ellipta Warnings/Precautions

    Warnings/Precautions

    LABA as monotherapy (without ICS) for asthma can increase risk of asthma-related events. Do not initiate in rapidly deteriorating or life-threatening COPD episodes. Prescribe a short-acting, inhaled β2-agonist for acute symptoms; monitor for increased need. Do not exceed recommended dose. Avoid use with other long-acting β2-agonists. Discontinue if paradoxical bronchospasm occurs; use alternative therapy. Cardiovascular disorders (esp. coronary insufficiency, arrhythmias, hypertension). Convulsive disorders. Thyrotoxicosis. Hyperresponsiveness to sympathomimetics. Diabetes. Ketoacidosis. Narrow-angle glaucoma. Urinary retention. Prostatic hyperplasia. Bladder-neck obstruction. Risk of hypokalemia or hyperglycemia. Labor & delivery. Pregnancy. Nursing mothers: not recommended.

    Anoro Ellipta Pharmacokinetics

    See Literature

    Anoro Ellipta Interactions

    Interactions

    Caution with concomitant strong CYP3A4 inhibitors (eg, ketoconazole, ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, voriconazole), MAOIs, tricyclic antidepressants, drugs known to prolong the QT interval or within 2 weeks of discontinuing such agents (increased cardiac effects), K+-depleting diuretics. Antagonized by β-blockers; if needed, consider cardioselective agents. Additive effects with concomitant other anticholinergic-containing drugs; avoid.

    Anoro Ellipta Adverse Reactions

    Adverse Reactions

    Pharyngitis, sinusitis, lower respiratory tract infection, constipation, diarrhea, pain in extremity, muscle spasms, neck and chest pain; hypersensitivity reactions (discontinue if occurs).

    Anoro Ellipta Clinical Trials

    See Literature

    Anoro Ellipta Note

    Not Applicable

    Anoro Ellipta Patient Counseling

    See Literature

    Images

    • Latest News Your top articles for Wednesday

    • Haymarket Medical NetworkTop Picks

    • Loading...

      Continuing Medical Education (CME/CE) Courses

      Show More